Willingness to pay for an Ebola vaccine during the 2014–2016 ebola outbreak in West Africa

Results from a U.S. National sample

Julia E. Painter, Michael E. von Fricken, Suyane Viana de O. Mesquita, Ralph DiClemente

Research output: Contribution to journalArticle

Abstract

The 2014–2016 Ebola virus outbreak in West Africa led to advances in the development of vaccines against Ebola. This study examined factors associated with willingness to pay for an Ebola vaccine among a U.S. national sample during the recent Ebola outbreak. From April 30–May 8, 2015, a national survey was conducted using the GfK Group's KnowlegePanel®. Main outcome measures included willingness to pay at least $1; more than $50; and more than $100 for an Ebola vaccine. Analyses were conducted using weighted multivariable logistic regression. Among participants (N = 1,447), 583 (40.3%) would not pay for an Ebola vaccine; 864 (59.7%) would pay at least $1. Among those willing to pay at least $1: 570 (66.0%) would pay $1–50; 174 (20.1%) would pay $51–100; and 120 (13.9%) would pay more than $100. Willingness to pay at least $1 for an Ebola vaccine was associated with international travel; interest in getting an Ebola vaccine; and beliefs that the U.S. government should spend money to control Ebola and assume worldwide leadership in confronting emerging epidemics. Willingness to pay more than $50 was associated with similar variables. Willingness to pay more than $100 was associated with international travel; interest in getting an Ebola vaccine; information seeking; and beliefs that the U.S. government should assume worldwide leadership in confronting emerging epidemics. International travel and interest in an Ebola vaccine were key predictors of willingness to pay across all price points. Understanding willingness to pay for vaccines against emerging infectious diseases remains critical.

Original languageEnglish (US)
Pages (from-to)1665-1671
Number of pages7
JournalHuman Vaccines and Immunotherapeutics
Volume14
Issue number7
DOIs
StatePublished - Jul 3 2018

Fingerprint

Ebola Vaccines
Western Africa
Disease Outbreaks
Ebolavirus
Emerging Communicable Diseases
Vaccines
Logistic Models

Keywords

  • attitudes
  • beliefs
  • Ebola
  • vaccine
  • willingness to pay

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Willingness to pay for an Ebola vaccine during the 2014–2016 ebola outbreak in West Africa : Results from a U.S. National sample. / Painter, Julia E.; von Fricken, Michael E.; Viana de O. Mesquita, Suyane; DiClemente, Ralph.

In: Human Vaccines and Immunotherapeutics, Vol. 14, No. 7, 03.07.2018, p. 1665-1671.

Research output: Contribution to journalArticle

@article{6bcfe2cb20684ec8b8e64fd5e3249b89,
title = "Willingness to pay for an Ebola vaccine during the 2014–2016 ebola outbreak in West Africa: Results from a U.S. National sample",
abstract = "The 2014–2016 Ebola virus outbreak in West Africa led to advances in the development of vaccines against Ebola. This study examined factors associated with willingness to pay for an Ebola vaccine among a U.S. national sample during the recent Ebola outbreak. From April 30–May 8, 2015, a national survey was conducted using the GfK Group's KnowlegePanel{\circledR}. Main outcome measures included willingness to pay at least $1; more than $50; and more than $100 for an Ebola vaccine. Analyses were conducted using weighted multivariable logistic regression. Among participants (N = 1,447), 583 (40.3{\%}) would not pay for an Ebola vaccine; 864 (59.7{\%}) would pay at least $1. Among those willing to pay at least $1: 570 (66.0{\%}) would pay $1–50; 174 (20.1{\%}) would pay $51–100; and 120 (13.9{\%}) would pay more than $100. Willingness to pay at least $1 for an Ebola vaccine was associated with international travel; interest in getting an Ebola vaccine; and beliefs that the U.S. government should spend money to control Ebola and assume worldwide leadership in confronting emerging epidemics. Willingness to pay more than $50 was associated with similar variables. Willingness to pay more than $100 was associated with international travel; interest in getting an Ebola vaccine; information seeking; and beliefs that the U.S. government should assume worldwide leadership in confronting emerging epidemics. International travel and interest in an Ebola vaccine were key predictors of willingness to pay across all price points. Understanding willingness to pay for vaccines against emerging infectious diseases remains critical.",
keywords = "attitudes, beliefs, Ebola, vaccine, willingness to pay",
author = "Painter, {Julia E.} and {von Fricken}, {Michael E.} and {Viana de O. Mesquita}, Suyane and Ralph DiClemente",
year = "2018",
month = "7",
day = "3",
doi = "10.1080/21645515.2018.1423928",
language = "English (US)",
volume = "14",
pages = "1665--1671",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "7",

}

TY - JOUR

T1 - Willingness to pay for an Ebola vaccine during the 2014–2016 ebola outbreak in West Africa

T2 - Results from a U.S. National sample

AU - Painter, Julia E.

AU - von Fricken, Michael E.

AU - Viana de O. Mesquita, Suyane

AU - DiClemente, Ralph

PY - 2018/7/3

Y1 - 2018/7/3

N2 - The 2014–2016 Ebola virus outbreak in West Africa led to advances in the development of vaccines against Ebola. This study examined factors associated with willingness to pay for an Ebola vaccine among a U.S. national sample during the recent Ebola outbreak. From April 30–May 8, 2015, a national survey was conducted using the GfK Group's KnowlegePanel®. Main outcome measures included willingness to pay at least $1; more than $50; and more than $100 for an Ebola vaccine. Analyses were conducted using weighted multivariable logistic regression. Among participants (N = 1,447), 583 (40.3%) would not pay for an Ebola vaccine; 864 (59.7%) would pay at least $1. Among those willing to pay at least $1: 570 (66.0%) would pay $1–50; 174 (20.1%) would pay $51–100; and 120 (13.9%) would pay more than $100. Willingness to pay at least $1 for an Ebola vaccine was associated with international travel; interest in getting an Ebola vaccine; and beliefs that the U.S. government should spend money to control Ebola and assume worldwide leadership in confronting emerging epidemics. Willingness to pay more than $50 was associated with similar variables. Willingness to pay more than $100 was associated with international travel; interest in getting an Ebola vaccine; information seeking; and beliefs that the U.S. government should assume worldwide leadership in confronting emerging epidemics. International travel and interest in an Ebola vaccine were key predictors of willingness to pay across all price points. Understanding willingness to pay for vaccines against emerging infectious diseases remains critical.

AB - The 2014–2016 Ebola virus outbreak in West Africa led to advances in the development of vaccines against Ebola. This study examined factors associated with willingness to pay for an Ebola vaccine among a U.S. national sample during the recent Ebola outbreak. From April 30–May 8, 2015, a national survey was conducted using the GfK Group's KnowlegePanel®. Main outcome measures included willingness to pay at least $1; more than $50; and more than $100 for an Ebola vaccine. Analyses were conducted using weighted multivariable logistic regression. Among participants (N = 1,447), 583 (40.3%) would not pay for an Ebola vaccine; 864 (59.7%) would pay at least $1. Among those willing to pay at least $1: 570 (66.0%) would pay $1–50; 174 (20.1%) would pay $51–100; and 120 (13.9%) would pay more than $100. Willingness to pay at least $1 for an Ebola vaccine was associated with international travel; interest in getting an Ebola vaccine; and beliefs that the U.S. government should spend money to control Ebola and assume worldwide leadership in confronting emerging epidemics. Willingness to pay more than $50 was associated with similar variables. Willingness to pay more than $100 was associated with international travel; interest in getting an Ebola vaccine; information seeking; and beliefs that the U.S. government should assume worldwide leadership in confronting emerging epidemics. International travel and interest in an Ebola vaccine were key predictors of willingness to pay across all price points. Understanding willingness to pay for vaccines against emerging infectious diseases remains critical.

KW - attitudes

KW - beliefs

KW - Ebola

KW - vaccine

KW - willingness to pay

UR - http://www.scopus.com/inward/record.url?scp=85042131081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042131081&partnerID=8YFLogxK

U2 - 10.1080/21645515.2018.1423928

DO - 10.1080/21645515.2018.1423928

M3 - Article

VL - 14

SP - 1665

EP - 1671

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 7

ER -